Published in final edited form as:

J Heart Lung Transplant. 2018 August ; 37(8): 1029–1034. doi:10.1016/j.healun.2018.03.019.

A low resistance, concentric-gated pediatric artificial lung for end-stage lung failure

Alex J. Thompson¹, Skylar Buchan¹, Benjamin Carr¹, Clinton Poling¹, McKenzie Hayes¹, U. Piyumindri Fernando¹, Andreas Kaesler², Peter Schlanstein², Felix Hesselmann², Jutta Arens², Joseph A. Potkay¹, Alvaro Rojas-Pena¹, Robert H. Bartlett¹, Ronald B. Hirschl¹

¹Extracorporeal Life Support Laboratory, Department of Surgery, University of Michigan, Ann Arbor.

²Department of Cardiovascular Engineering, Institute of Applied Medical Engineering, Helmholtz Institute, RWTH Aachen University, Aachen, Germany

Abstract

Children with end-stage lung failure awaiting lung transplant would benefit from improvements in artificial lung technology allowing for wearable pulmonary support as a bridge-to-transplant therapy. In this work we designed, fabricated, and tested the Pediatric MLung – a dual-inlet hollow fiber artificial lung based on concentric gating, which has a rated flow of 1 L/min, and a pressure drop of 25 mmHg at rated flow. This device, and future iterations of the current design, are designed to relieve pulmonary arterial hypertension, provide pulmonary support, reduce ventilator-associated injury, and allow for more effective therapy of patients with end-stage lung disease, including bridge-to-transplant treatment.

Keywords

Hollow fiber oxygenator; extracorporeal life support; wearable artificial lung

Introduction

One in five children with end-stage lung failure (ESLF) die while awaiting transplant.¹ Hollow fiber oxygenators, or artificial lungs (ALs), are commonly used to provide pulmonary support in acute and bridge-to-transplant applications. In these devices, blood flows around a bundle of hollow fibers, while a sweep gas supplied to the fibers' lumens facilitates gas transfer via diffusion through the fiber wall. The benefits of a particular AL depend on the design properties and engineering of the AL, and device development must be thoughtfully targeted to the intended patient population to achieve optimal results. In this work, we design, fabricate, and test the performance of a paracorporeal, pumpless device intended for pediatric patients. This device, called the "Pediatric MLung," can be used as a bridge to transplant for children with ESLF.

Conflict of Interest Statement: The authors of this work have no conflicts of interest to disclose.

The Pediatric MLung is designed to be attached via a pulmonary artery (PA) to left atrium (LA) configuration. The PA-LA configuration is advantageous because it is attached in parallel to the native lung, such that high pressure in the right ventricle (RV) is relieved due to the availability of a flow path of lower resistance.² Additionally, the PA-LA configuration provides a pressure gradient for device blood flow, so that it can be operated without a blood pump. This configuration has been demonstrated previously;^{3–7} however, improvements in the technology are needed as mortality rates remain high due to clot formation and stroke caused by inefficiencies in AL configuration and flow. Development of smaller, more efficient devices is advantageous, as reduction of priming volume and blood-contacting surface area in ALs has been shown to improve patient outcomes in cardiopulmonary bypass procedures.^{8–11} Additionally, the ALs used for this application have been too bulky to allow for patient ambulation, which has been shown to be important in preparing patients for lung transplantation.^{12,13} A wearable AL would be advantageous for children as a bridge-to-lung transplant because it would: 1) supplement pulmonary function of the diseased native lungs; 2) facilitate ambulation during bridge to transplant or even as a destination device; 3) improve portability and reduce blood trauma by eliminating a mechanical pump^{14,15}; 4) avoid ventilator-associated events by allowing the patient to be extubated^{2,16}; and 5) allow support outside of the ICU and even potentially outside of the hospital.

To function without a mechanical pump, the device and circuit must have a low enough resistance that the pressure gradient between the PA and LA, generated by the right ventricle, is sufficient to drive adequate flow through the device. Assuming a mean PA pressure of at least 25 mmHg (although hypertension in this patient population can produce mean PA pressures above 70 mmHg)¹⁷ and LA pressure of 10 mmHg, the entire circuit (including MLung, tubing, and cannulas) must have a pressure drop less than 15 mmHg, however a circuit of even lower resistance is beneficial due to the alleviation of RV load. In order to meet the desired resistance of the entire circuit, our target for the Pediatric MLung itself is a pressure drop of 5 mmHg at rated flow. Rated flow refers to the blood flow rate at which blood entering the device at an oxygen saturation (sO_2) of 70% exits the device at sO_2 of 95%.¹⁸ The target rated flow for the Pediatric MLung is 0.75 L/min, which equates to up to 50 mL/min of oxygen transfer. This target is based on the oxygen demand of a typical pediatric patient,¹⁹ and would allow the Pediatric MLung to manage all the oxygenation of the patient if necessary.

The PA-LA attachment requires a device that has low resistance to flow. This can be problematic from a design perspective because device resistance increases with fiber number and density, both of which directly impact the gas exchange capability of the device. Additionally, current hollow fiber devices are limited by the “boundary layer effect” wherein the resistance to diffusion-based gas transfer is increased due to a plasma rich layer devoid of red blood cells (RBC) in close proximity to the fiber membranes.²⁰ To overcome this problem, researchers have investigated methods to induce secondary flows in the devices to disrupt the formation of this boundary layer.²⁰ These efforts include passive methods such as increasing the surface area to volume (SA/V) ratio of the blood flow path (i.e. microfluidic lungs), increasing flow velocity across the fiber bundle, including obstacles in the flow path, and membrane texturing; and active methods such as building oxygenators with enclosed rotating discs and perfusing the devices with pulsatile flow.^{21–25} Recently, we demonstrated

a membrane lung based on a series of concentric gates, resulting in a circular blood flow path that induces secondary flows, disrupting the boundary layer, and improving overall gas exchange.²⁶ Based on our previous work, this study aims for designing a new artificial lung that provides adequate gas exchange and pressure drop for pediatric patients.

Materials and Methods

Computational Fluid Dynamics (CFD)

A solid 3D model of the Pediatric MLung device was built in Solidworks and CFD simulation was carried out using Solidworks Flow Simulation add-in. The fiber bundle area was modeled as a continuous porous media. The resistance of the fiber bundle to be used in the porous media model was estimated using previous experimental data and **Equations 1–3**,²⁷

$$\Delta P = - \frac{\mu Q L}{\kappa A} \quad (1)$$

$$\kappa = \frac{\varepsilon^3 D_p^2}{A(1 - \varepsilon)^2} \quad (2)$$

$$A = 497\varepsilon - 103 \quad (3)$$

where ΔP = pressure drop, μ = blood viscosity, Q = volumetric flow rate, L = blood path length, κ = fiber bundle permeability, ε = fiber bundle porosity, and D_p = effective particle diameter (estimated as 1.5 times the fiber diameter).²⁸

In order to accurately model pressure drop within the fiber bundle, resistance data for the fiber bundle is typically determined by experimental measurements.²⁹ These measured values are then input into the porous media model. Data from our previous work was used to provide the necessary resistance data to simulate the fiber bundle as an isotropic porous media.²⁶ The experimental resistance data for the original fiber mat (17 fib/cm) was scaled down linearly by multiplying by a factor (κ/κ_{LR}) where κ_{LR} is the predicted permeability of the low resistance fiber mat (6 fib/cm) into Equation 1. This provided the resistance data for the low resistance fiber mat to be input into the porous media model for the CFD simulations.

Blood flow was simulated using the predefined blood model in Solidworks Engineering Database. Blood is modeled as a non-Newtonian fluid having density is 1060 kg/m³. Viscosity is calculated using a power law model, with max dynamic viscosity of .012 Pa·s, min dynamic viscosity of 0.003 Pa·s, and power law index of 0.7991.

Boundary conditions were an inlet flow rate of 0.75 L/min at the device inlets (0.375 L/min at each inlet), and a pressure of 10 mmHg at the device outlet. The automatic mesh function in Solidworks was used to generate the mesh, which has incremental settings between 1–7 (7 providing the most refined mesh). A grid independence study was performed which determined that the automatic mesh setting should be 3. Due to reasonable computational time (~8 min), a mesh setting of 5 was used, which produced 356686 fluid cells in the computational domain.

Basic Device Topology

The Pediatric MLung is composed of 5 housing parts, an inner and outer fiber bundle, and a liquid curing silicone (referred to as “potting”) which separates the blood and sweep gas flow paths. The Pediatric MLung components are (a) outer housing (with blood inlets), (b) gate insert, (c) blood outlet, and (d,e) two end caps (Figure 1). The fiber bundles are packed between outer housing, gate insert, and blood outlet. The thicknesses of the inner and outer bundles are equivalent (2.3 cm). Two thirds of the total membrane surface area is in the outer bundle and one third is in the smaller inner bundle. The potting is applied to the ends of the fiber bundle as a liquid in order to fill in the tight spaces in between fibers. The potting then hardens at room temperature to form a barrier between the blood and gas phases to prevent blood leakage or air emboli formation in the blood.

MLung Fabrication

3D computer-aided design (3D CAD) models of the housing components were built using Solidworks. Polyurethane housing components were injection molded (Stratasys Direct Manufacturing). Polymethyl pentene (PMP) fiber mat (6 fibers/cm) was obtained from Membrana (OXYPLUS®). Potting fixture components were 3D printed using M3 crystal resin and a ProJet 3500 HD Max 3D printer (UM3D print lab at the University of Michigan).

PMP fibers were hand-wound around the gate insert and blood outlet components (see Figure 1) until snug within the fiber bundle area, taking care to prevent wrinkles in the fiber mat that would cause irregularity in the fiber bundle. The Pediatric MLung was then seated within a potting fixture, using temporary metal pins to suspend the gate insert to maintain proper alignment with the outer housing and blood outlet pieces during the potting process. A custom centrifuge was used to supply liquid silicone potting (Wacker, Elastosil RT625) to the ends of the fiber bundle. The silicone hardens at room temperature, while centrifugal force prevents liquid potting from creeping up the outsides of the fibers. To prevent creep of potting within the fiber lumens, the fiber ends were sealed using a heated metal edge prior to packing within the Pediatric MLung. Potting was introduced to the inlet reservoir tubing immediately after mixing (see Figure 1). Devices were centrifuged for 2 hours and then allowed to sit overnight at room temperature. Devices were then removed from the potting fixture and the excess potting was cut flush to the outer housing to expose the fiber lumens for sweep gas. End caps were affixed to the completed Pediatric MLungs.

Prior to benchtop performance testing or *in-vivo* testing, the blood side of the Pediatric MLung was flushed with at least 1L of sterile saline and then primed with sterile saline.

Benchtop Performance Testing

A benchtop flow circuit using slaughterhouse bovine blood was used to test gas exchange and pressure drop performance at various blood and sweep flow rates. Prior to bench testing, blood was filtered with a 32 μm mesh (Capiiox arterial filter removed from a Capiiox FX25 oxygenator), preconditioned to standard venous values (per ISO7199/FDA Guidelines³⁰), and heparinized as necessary to an activated clotting time (ACT) >1500 s. Heparinized blood from an inlet reservoir was directed to a centrifugal pump, which pumped blood to the test device and then to an outlet reservoir at programmed flow rates. Sweep gas was supplied to the Pediatric MLung from compressed gas tanks and controlled using a mass flow controller (Alicat Scientific, Model MCP-50SLPM, D/10M). Sweep gas was supplied for each blood flow rate in a 2:1, 4:1, and 8:1 blood flow ratio. Blood flow rates of 0.5, 0.75, and 1 L/min were used. If device rated flow was either below 0.5 L/min or above 1 L/min, then blood flow rates of 0.25 L/min or 1.25 L/min were added, respectively. Pre- and post-device blood gas samples were collected via sampling ports in the tubing and analyzed using a Radiometer ABL800flex blood gas analyzer. Pre- and post-device blood-side pressure was monitored using Transpac® disposable pressure transducers. ACT was measured using an Accriva Hemochron Response whole blood coagulation system.

In-vivo Hemocompatibility and Performance Testing

All protocols were approved by the University of Michigan Committee on Care and Use of Animals, and animals received humane care in accordance with the NIH Guide for the Care and Use of Laboratory Animals.

Healthy, fasted adult sheep (38–42 kg) were sedated using intravenous propofol (5–10 mg/kg) and intubated. General anesthesia was maintained using inhaled isoflurane (1–3.5%). The right femoral artery was accessed using 14 Fr Bio-medicus arterial cannula (Medtronic, Minneapolis, MN) and the right jugular vein was cannulated with a 20 Fr DLP venous cannula (Medtronic, Minneapolis, MN), both via cut-down technique. A femoral-artery-to-jugular-vein extracorporeal circuit was constructed, incorporating the Pediatric MLung. For experiments utilizing the PA-LA configuration, cannulation was performed through an end-to-side anastomosis with either Dacron or PTFE graft. Occlusion of the right pulmonary artery (rPA) was used as previously described as a disease model for end stage lung failure.⁵ The circuit was completely deaired and primed using approximately 200 mL sterile saline prior to opening arteriovenous flow. Solumedrol was administered (750 mg IV, 250 mg through the device inlet pressure port) immediately prior to opening blood flow to the Pediatric MLung circuit. This is done to prevent any acute allergic reaction from the sheep that could affect hemodynamics (which can occur because the devices are not sterile and there is a possibility of leaching of fabrication materials). Sheep were heparinized to an activated clotting time (ACT) consistent with clinical ECMO (ACT 200–240 s).³¹ Prior to initiating shunt flow through the Pediatric MLung, minute ventilation was set to a standard baseline value of 7.2 L/min. Minute ventilation was reduced by 33% by decreasing respiratory rate in order to induce hypercapnia, and vecuronium bromide was administered (3 mg IV, subsequent IV drip at 1.5 mg/ml) to prevent spontaneous breathing of the animal with rising blood pCO_2 . When arterial pCO_2 reached a stable value (same pCO_2 for 15 minutes), arteriovenous blood flow was opened to the MLung circuit. Target arterial pCO_2

prior to initiating flow to the MLung was 50–60 mmHg in order to test ventilation capability of the Pediatric MLung during hypercapnia. Sweep flow was controlled via mass flow controller (Alicat Scientific, Model MCP-50SLPM, D/10M), which was set at 6 L/min for the first hour, 12 L/min for the second hour, and 2 L/min for the remaining duration of the experiment. Blood flow rate through the device was monitored using a flow meter (Transonic, Model T402) with flow probe (Transonic, ME 9PXL).

Blood gas samples, sweep gas exhaust samples, and ACT measurements were obtained every 15 minutes for 2 hours, then every 30 minutes for the duration of the experiment using a ABL800 Flex blood gas analyzer (Radiometer, Brea, CA) and Hemochron Response whole blood coagulation monitoring instrument (Accriva, Bedford, MA), respectively. CO₂ removal was measured as fraction of CO₂ in the exhaust sweep gas. Complete blood count (CBC) samples were collected every hour throughout the experiment using a Procyte Dx hematology analyzer (IDEXX, Westbrook, ME). The experiment was concluded at 6 hours or when the device blood flow was reduced to less than 5% of initial flow due to clotting. Immediately upon conclusion of the experiments, the Pediatric MLung was removed from the circuit and flushed via gravity in the opposite direction of blood flow using sterile saline (at least 2 L) to remove any blood or clot non-adherent within the device and photographed to document any residual thrombi. After gross imaging, the intact units were flushed with 10% bleach (1–2 hrs) followed by DI water (overnight) and compressed air (overnight) to clean prior to use in future experiments.

Results

Computational Fluid Dynamics

The required gas exchange surface area (SA) for the current device was estimated by scaling our previous design, which had a SA = 0.28 m² and a rated flow of 2 L/min, but a pressure drop of about 100 mmHg.²⁶ Scaling down SA linearly (assuming equivalent gas exchange efficiency in the previous and new designs) gave a basis SA of 0.1 m² for the new design, as this SA is expected to provide the necessary gas exchange to satisfy the rated flow requirement. Blood flow was simulated in Solidworks Flow Simulator, and velocity and pressure profiles were generated (Figure 2).

At 0.75 L/min, pressure drop in a single-inlet MLung using a fiber mat with 17 fib/cm and a fiber length of 2 cm was 38 mmHg (from previous work).²⁶ In order to further reduce pressure drop, three changes were made from the previously published design see Table 1: 1) the use of a dual-inlet design, 2) fiber length increased to 3 cm, and 3) reduction of the fiber bundle porosity by using a low-density fiber mat (6 fib/cm). Each of these changes independently reduces pressure drop, and when the fiber bundle is modeled as an isotropic porous media, a pressure drop of 2 mmHg is predicted at a flow rate of 0.75 L/min. Six Pediatric MLungs were successfully fabricated as described in Methods and used for benchtop and *in-vivo* testing.

Benchtop Testing

The Pediatric MLungs were performance tested using a previously described benchtop blood flow model.²⁶ Average rated flow of the 6 devices was 1 L blood/min (Figure 3). Average pressure drop ($\pm$ SE) at the target blood flow rate of 0.75 L/min was 18 ± 3 mmHg, and at the achieved rated flow of 1 L/min was 25 ± 4 mmHg. Average oxygenation rate and oxygenation efficiency were 45 mL/min and 350 mL/min/m²² at rated flow, respectively.

In-Vivo Testing and Hemocompatibility

The Pediatric MLungs were operated for 6 hours or until device flow was reduced to 5% of initial flow due to clotting (Figure 4). Average initial device flow (T0) was 0.8 ± 0.1 L/min ($n = 3$) at an average initial pressure drop of 11 ± 4 mmHg. Devices A and B were used for the entire 6-hour experiment, and device C was used for 3.5 hours before the rapid decrease in blood flow (due to clotting) indicated an experimental endpoint (device flow = 5% of initial flow). Flow resistance of the devices was initially 13 ± 3 mmHg·min·L⁻¹, which increases when clotting in the Pediatric MLung or blood circuit occurs (Figure 5). Six hours of device flow resulted in a 31% and 27% decrease in platelet count from the initial (T0) value for sheep with devices A and B attached, respectively, and a decrease in platelet count of 29% occurred within 3 hours in the device C sheep (Figure 6). White blood cell count decreased by 34%, 0% (no change), and 8% in sheep attached to devices A, B, and C, respectively. Average CO₂ removal efficiency was initially 420 ± 42 mL/min/m²² and gradually decreased throughout the course of the experiment (Figure 7). Following the experiments, devices were rinsed with saline as described in Methods and imaged (Supplemental Figure 1). Pediatric MLungs tested in the PA-LA configuration achieved a maximum of 0.383 ± 0.02 L/min of blood flow through the circuit without rPA occlusion and 0.617 ± 0.02 L/min of circuit flow with full occlusion of the rPA (Figure 8).

Discussion

Oxygenator geometry, blood path length, fiber length and number (gas exchange SA), and fiber bundle density together determine the pressure drop and gas exchange capability of the artificial lung. Typically, ALs with high gas exchange capability also have a high pressure drop. By utilizing a concentric gated design, circular flow induces mixing which improves the overall gas exchange efficiency. Additionally, the concentric gating increases the blood flow path length, increasing both gas exchange and pressure drop. We offset this increase in pressure drop by utilizing (1) a dual-inlet design and (2) a low-density fiber mat. The dual-inlet design reduces resistance by splitting the flow, effectively shortening the average blood path length but maintaining the benefit of the concentric gating. This is evidenced in that the oxygenation efficiency in the Pediatric MLung is the same as the single-inlet MLung, in which the blood path length is roughly twice as long. The low-density fiber mat provides a fiber bundle with lower resistance. The resulting device meets the gas exchange specification, but operates above the target pressure drop. The current device still is clinically relevant in its current design as hypertensive patients may produce PA pressures above 70 mmHg.¹⁷ However, changes will be made to future iterations of the device in order to achieve target pressure drop to allow treatment of normotensive patients and reduce right ventricular (RV) load.

Gas exchange performance is comparable to our previous published AL design and is more efficient than current clinical devices (Table 2). Priming volume is comparable to clinical pediatric ALs, but will be reduced in future designs by making devices which are smaller in size but use a higher density fiber mat to meet specifications. Increasing the density of the fiber mat will increase pressure drop, but this will be offset by tuning other parameters such as fiber length and the length of the blood flow path. CO₂ removal efficiency gradually decreased throughout the course of the experiment, likely due to an increase in the resistance to CO₂ diffusion caused by water condensation in the gas phase, platelet deposition on the fiber surface, or a combination of both.

The pressure drop of the Pediatric MLungs was higher than predicted by CFD simulations. Slight differences between the intended and actual Pediatric MLung parameters (2.5±0.1 cm fibers rather than 3 cm, 0.13 m²² membrane SA rather than 0.10, porosity of 0.86 rather than 0.9) account for some of this difference in pressure drop. However, when these values are reflected in the simulations, CFD still predicts a lower pressure drop than what was experimentally observed. In the simulation, the fiber bundle is treated as a continuous, isotropic porous media rather than a collection of discrete fiber bundles. In practice, the fiber bundles have different permeabilities depending on the direction of blood flow. Additionally, the fibers in the device are not equally spaced. Although each adjacent fiber is equally spaced within the fiber mat (i.e. in the circumferential direction in the fiber bundle), as the fiber bundle is wrapped, the adjacent fibers in the radial direction are much closer together. This causes the estimated permeability to be different from the actual permeability of the non-homogenous fiber mat. In this cylindrical configuration the fiber bundle is more accurately modeled as an axisymmetric porous media or an anisotropic media³²; however, the resistance in each direction across the fiber bundle must be determined experimentally to accurately model the fiber bundle as an axisymmetric or anisotropic porous media.

Two Pediatric MLungs demonstrated use in the AV circuit over 6 hours and a third was used for 3.5 hours before clotting in the circuit caused flow to drop substantially. Platelet consumption was gradual but apparent in the three devices tested (31%, 27%, and 29% reduction in platelet count for devices A, B, and C, respectively), while a consistent trend regarding WBC concentration was not apparent. The clotting that was observed qualitatively occurred in three areas: 1) an area of apparent recirculating flow in the inlet of the device, 2) along the horizontal cross-threads that hold the fiber mat together, and 3) at areas adjacent to the potting (see Supplemental Figure 1). Future designs will include refinement of the inlet geometry to remove the area of recirculating flow. The fiber crossthreads are necessary for the integrity of the fiber mat, but can potentially be situated to be present only within the potting of the device and not in the active blood-contacting region. Longer-term animal studies are necessary to verify hemocompatibility for chronic applications. In this work, acute hemocompatibility/thrombosis is evaluated without the aid of non-thrombogenic coatings/sweep gas additives. However, future iterations of the Pediatric MLung including chronic hemocompatibility testing will incorporate a non-thrombogenic coating and the addition of nitric oxide to the sweep gas.

Much of the current work focuses on designing the Pediatric MLung so that it has a low resistance. While resistance is the opposition to steady flow, impedance can be thought of as

the opposition to pulsatile flow.^{33,34} Impedance is determined by both the resistance and compliance of the circuit (as well as parameters related to the fluid and pulsatility).^{35,36} Circuit compliance is an important consideration that has been shown to affect cardiac function and RV load, particularly for long term support.³⁷ This is seen in normal, healthy pulmonary circulation as well. In addition to having low resistance to steady flow (relative to systemic arterial circulation), the natural pulmonary circulation displays enhanced vascular distention (compliance) which is important in allowing pressures in these vessels to remain low.^{33,38} ALs that have higher than physiological impedances can produce abnormal pulmonary hemodynamics when connected in parallel or in series with the natural lung.³⁹ Compliant artificial lungs and circuits have been developed to achieve impedances even lower than the natural lung.^{40–42} Circuit compliance will be an important consideration for the development and implementation of the Pediatric MLung, however in this work we have focused solely on the resistance aspect of the artificial lung. Future work will done to incorporate the proper level of compliance to the circuit.

In conclusion, a pediatric artificial lung based on concentric gating (Pediatric MLung) was designed and fabricated. The device has a rated blood flow of 1 L/min and a pressure drop = 25 mmHg at rated flow. A dual-inlet design and low resistance fiber mat was used to keep pressure drop low while maintaining adequate gas exchange capability. We demonstrated repeatable fabrication (n = 6), confirmed performance in benchtop blood flow testing and in an acute sheep model of ECMO. The next step for this work will be implantation of the device in a chronic sheep model to demonstrate long-term pulmonary support.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

This work was funded by NIH grant 2R01 HD015434. Thanks to all of the University of Michigan ECLS lab technicians, fellows, UROP students, Surgery 499 students, and volunteers who have helped with this work. In particular, thanks to Mark Langley, Felicia Hinojosa, Rami Beydoun, and Devak Nanua for their help with *in-vivo* experiments. Thanks to Cindy Cooke for her support of this work, in particular with the preparation of grant proposals and manuscripts.

Source of Funding: National Institutes of Health 2R01 HD015434-34

References

1. Valapour M, Skeans MA, Smith JM, et al.: OPTN/SRTR 2015 Annual Data Report: Lung Am J Transplant, 2017
2. Alghanem F, Davis RP, Bryner BS, et al.: The Implantable Pediatric Artificial Lung: Interim Report on the Development of an End-Stage Lung Failure Model ASAIO J 61: 453–458, 2015 [PubMed: 25905495]
3. Boston US, Fehr J, Gazit AZ, Eghtesady P: Paracorporeal lung assist device: An innovative surgical strategy for bridging to lung transplant in an infant with severe pulmonary hypertension caused by alveolar capillary dysplasia J Thorac Cardiovasc Surg 146, 2013
4. Hoganson DM, Gazit AZ, Boston US, et al.: Paracorporeal lung assist devices as a bridge to recovery or lung transplantation in neonates and young children, in: Journal of Thoracic and Cardiovascular Surgery. Vol 147 2014, pp. 420–426. [PubMed: 24199759]

5. Alghanem F, Bryner BS, Jahangir EM, et al.: Pediatric Artificial Lung: A Low-Resistance Pumpless Artificial Lung Alleviates an Acute Lamb Model of Increased Right Ventricle Afterload. *ASAIO J* 63: 223–228, 2017 [PubMed: 27861431]
6. Hoganson DM, Gazit AZ, Sweet SC, Grady RM, Huddleston CB, Eghtesady P: Neonatal paracorporeal lung assist device for respiratory failure *Ann Thorac Surg* 95: 692–694, 2013 [PubMed: 23336880]
7. Gazit AZ, Sweet SC, Grady RM, Huddleston CB: First experience with a paracorporeal artificial lung in a small child with pulmonary hypertension *J Thorac Cardiovasc Surg* 141, 2011
8. Hsu LC: Biocompatibility in cardiopulmonary bypass *J Cardiothorac Vasc Anesth*, 1997
9. Cormack JE, Forest RJ, Groom RC, Morton J: Size makes a difference: Use of a low-prime cardiopulmonary bypass circuit and autologous priming in small adults *Perfusion*, 2000
10. Jansen PGM, te Velthuis H, Bulder ER, et al.: Reduction in prime volume attenuates the hyperdynamic response after cardiopulmonary bypass *Ann Thorac Surg*, 1995
11. Shapira OM, Aldea GS, Treanor PR, et al.: Reduction of allogeneic blood transfusions after open heart operations by lowering cardiopulmonary bypass prime volume *Ann Thorac Surg*, 1998
12. Rehder KJ, Turner DA, Hartwig MG, et al.: Active rehabilitation during ECMO as a bridge to lung transplantation *Respir Care*, 2012
13. Olsson KM, Simon A, Strueber M, et al.: Extracorporeal membrane oxygenation in nonintubated patients as bridge to lung transplantation *Am J Transplant* 10: 2173–2178, 2010 [PubMed: 20636463]
14. Fraser CD Jr., Jaquiss RD, Rosenthal DN, et al.: Prospective trial of a pediatric ventricular assist device *N Engl J Med* 367: 532–541, 2012 [PubMed: 22873533]
15. Chen JM, Richmond ME, Charette K, et al.: A decade of pediatric mechanical circulatory support before and after cardiac transplantation *J Thorac Cardiovasc Surg* 143: 344–351, 2012 [PubMed: 22143101]
16. Elizur A, Sweet SC, Huddleston CB, et al.: Pre-transplant Mechanical Ventilation Increases Short-term Morbidity and Mortality in Pediatric Patients With Cystic Fibrosis *J Heart Lung Transplant* 26: 127–131, 2007
17. Berger RMF, Beghetti M, Humpl T, et al.: Clinical features of paediatric pulmonary hypertension: A registry study *Lancet*, 2012
18. Federspiel WJ, Henchir KA: Lung, artificial: basic principles and current applications, in: *Encyclopedia of Biomaterials and Biomedical Engineering*: LZ. 2004.
19. McMurray RG, Butte NF, Crouter SE, et al.: Exploring metrics to express energy expenditure of physical activity in youth *PLoS One*, 2015
20. Wegner JA: Oxygenator anatomy and function *J Cardiothorac Vasc Anesth*, 1997
21. Richardson PD, Galletti PM: Correlation of effects of blood flow rate, viscosity and design features on artificial lung performance, in: *DAWIDS SG, ENGELL HCBT-P and CA of OD (eds) Elsevier*, 1976, pp. 29–44.
22. Tanishita K, Nakano K, Richardson PD, Galletti PM, Sugawara M, Sakurai Y: Augmentation of Gas Transfer With Pulsatile Flow in the Coiled Tube Membrane Oxygenator Design *ASAIO J* 26, 1980
23. Bellhouse BJ, Bellhouse FH, Curl CM, et al.: A High Efficiency Membrane Oxygenator and Pulsatile Pumping System, and Its Application to Animal Trials *ASAIO J* 19, 1973
24. Moss RA, Benn JA, Ghadar FK, Drinker PA: Secondary Flow and Mass Transfer in an Oscillating Torus *Adv Cardiol* 6: 40–55, 1971
25. Schraven L, Kaesler A, Flege C, et al.: Effects of Pulsatile Blood Flow on Oxygenator Performance *Artif Organs* 42: 410–419, 2018 [PubMed: 29436001]
26. Fernando UP, Thompson AJ, Potkay J, et al.: A Membrane Lung Design Based on Circular Blood Flow Paths *ASAIO J*, 2017
27. Madhani SP, D'Aloiso BD, Frankowski B, Federspiel WJ: Darcy permeability of hollow fiber membrane bundles made from Membrana Polymethylpentene fibers used in respiratory assist devices *ASAIO J* 62: 329–331, 2016 [PubMed: 26809086]

28. Pacella HE, Eash HJ, Frankowski BJ, Federspiel WJ: Darcy permeability of hollow fiber bundles used in blood oxygenation devices J Memb Sci, 2011
29. Schlanstein PC, Limper A, Hesselmann F, Schmitz-Rode T, Steinseifer U, Arens J: Experimental method to determine anisotropic permeability of hollow fiber membrane bundles J Memb Sci 546: 70–81, 2018
30. Guidance for Cardiopulmonary Bypass Oxygenators 510(k) Submissions; Final Guidance for Industry and FDA Staff., 2000.
31. ELSO Anticoagulation Guideline: ELSO Guidel, 2014 Available at: <https://www.else.org/Portals/0/Files/elseanticoagulationguideline8-2014-table-contents.pdf>. Accessed March 7, 2018.
32. Bhavsar SS, Schmitz-Rode T, Steinseifer U: Numerical Modeling of Anisotropic Fiber Bundle Behavior in Oxygenators Artif Organs, 2011
33. Milnor WR: Pulsatile blood flow. N Engl J Med 287: 27–34, 1972 [PubMed: 4555147]
34. Haft JW, Bull JL, Rose R, et al.: Design of an artificial lung compliance chamber for pulmonary replacement ASAIO J, 2003
35. McGillicuddy JW, Chambers SD, Galligan DT, Hirschl RB, Bartlett RH, Cook KE: In vitro fluid mechanical effects of thoracic artificial lung compliance ASAIO J, 2005
36. Haft JW, Alnajjar O, Bull JL, Bartlett RH, Hirschl RB: Effect of artificial lung compliance on right ventricular load ASAIO J, 2005
37. Sato H, Hall CM, Lafayette NG, et al.: Thirty-Day In-Parallel Artificial Lung Testing in Sheep Ann Thorac Surg, 2007
38. Kussmaul WG, Noordergraaf A, Laskey WK: Right ventricular-pulmonary arterial interactions Ann Biomed Eng, 1992
39. Schewe RE, Khanafer KM, Orizondo RA, Cook KE: Thoracic artificial lung impedance studies using computational fluid dynamics and in vitro models Ann Biomed Eng, 2012
40. Scipione CN, Schewe RE, Koch KL, Shaffer AW, Iyengar A, Cook KE: Use of a low-resistance compliant thoracic artificial lung in the pulmonary artery to pulmonary artery configuration J Thorac Cardiovasc Surg, 2013
41. Schewe RE, Khanafer KM, Arab A, Mitchell JA, Skoog DJ, Cook KE: Design and in vitro assessment of an improved, low-resistance compliant thoracic artificial lung ASAIO J, 2012
42. Akay B, Foucher JA, Camboni D, Koch KL, Kawatra A, Cook KE: Hemodynamic design requirements for in-series thoracic artificial lung attachment in a model of pulmonary hypertension ASAIO J, 2012
43. Sun L, Kaesler A, Fernando P, Thompson AJ, Toomasian JM, Bartlett RH: CO2 clearance by membrane lungs Perfusion 33: 249–253, 2018 [PubMed: 29090614]
44. Wei X, Sanchez PG, Liu Y, et al.: Extracorporeal Respiratory Support With a Miniature Integrated Pediatric Pump-Lung Device in an Acute Ovine Respiratory Failure Model Artif Organs 40: 1046–1053, 2016 [PubMed: 27087252]
45. Orizondo RA, May AG, Madhani SP, et al.: In Vitro Characterization of the Pittsburgh Pediatric Ambulatory Lung ASAIO J, 2018
46. May AG, Orizondo RA, Frankowski BJ, Wearden PD, Federspiel WJ: Acute In Vivo Evaluation of the Pittsburgh Pediatric Ambulatory Lung. ASAIO J, 2018

Figure 1.

(A,B) Basic device topology of the Pediatric MLung including (a) outer housing, (b) gate insert, (c) blood outlet, (d,e) end caps, (f) fiber bundles, and (g) the blue silicone potting. (C) Side view of a Pediatric MLung, the fibers are oriented vertically within the housing in this image. (D) Top view of a Pediatric MLung with illustration of the blood flow path (red arrows).

Figure 2. Isometric views of the 3D model (A) and a cross-section through a midplane (B) of the pediatric MLung having 3 cm fiber length. Velocity (C) and pressure (D) profiles through the mid-plane of the Pediatric MLung were generated with Solidworks Flow Simulation.

Figure 3. Oxygenation (A, B) and pressure drop (C) of pediatric MLung during benchtop blood flow testing. (n = 6)

Figure 4.

Device flow rate (circles) and corresponding pressure drop (triangles) during 6 hours of arteriovenous blood flow from adult sheep. Three Pediatric MLungs were tested (A, B, C) for 6 hours or until device flow was reduced to 5% of initial flow.

Figure 5.

Systemic ACT (circles) and device resistance (triangles) during 6 hours of arteriovenous blood flow from adult sheep. Three Pediatric MLungs were tested (A, B, C) for 6 hours or until device flow was reduced to 5% of initial flow.

Figure 6.

Platelet count (circles) and WBC count (triangles) during 6 hours of arteriovenous blood flow from adult sheep. Three Pediatric MLungs were tested (A, B, C) for 6 hours or until device flow was reduced to 5% of initial flow.

Figure 7.

CO₂ Removal efficiency (circles) at varied sweep flow (triangles) of three Pediatric MLungs that were tested for 6 hours or until device flow was reduced to 5% of initial flow.

Datapoints not gathered were due to dilution of the sample by sweep gas making the collected CO₂ concentration below the detection limit of the blood gas machine. (average $\pm$ SEM, n = 3, *n = 2, no error bar: n = 1)

Figure 8.

Device flow rate (diamonds) and corresponding pressure drop (squares) during 6 hours of blood flow from adult sheep. Three Pediatric MLungs were tested (A, B, C) for 6 hours (with exception of plot C, in which the experiment was ended voluntarily after occlusion of the rPA did not result in blood flow of at least 0.75 L/min). Oxygenation rate was measured throughout each experiment (D).

Table I.

CFD-predicted pressure drop and shear stress in the Pediatric MLung using target values for fiber length, porosity, and surface area (**bold**). After fabricating devices (n=6), the simulation was run using experimentally achieved values (italics; average $\pm$ SD, n=6) for fiber length, porosity, and surface area in the fabricated devices. *Experimentally measured data²⁶ **Pressure and shear values for the fabricated devices are from CFD simulation using the achieved fiber length and porosity values

Inlet Configuration	Porosity	κ (cm ²)	Fiber Length (cm)	Fiber Mat Density (fiber/cm)	Surface Area (m ²)	Pressure Drop (mmHg)	Shear Stress (dyn/cm ²)	
							Max	Average
Single Inlet ²⁶	0.58	2×10^{-9}	2	17	0.28	38*	-	-
Dual Inlet (target)	0.9	7×10^{-8}	3	6	0.10	4.03	53	8.3
<i>Dual Inlet (measured)</i>	<i>0.85$\pm$.003</i>	<i>3×10^{-8}</i>	<i>2.5$\pm$0.3</i>	<i>6</i>	<i>0.13$\pm$0.02</i>	8.71**	67**	7.0**

Table II.

‡Novalung iLA is designed for CO₂ removal and data at rated flow was not available, therefore the CO₂ removal at the max flow for which data was available was reported. *CO₂ exchange efficiency for the Pedipump lung was estimated from Wei et al (2016).⁴⁴ **Rated flow was not reported for the P-PAL, however gas exchange efficiency was comparable to the PediPL at a flow rate of 2 L/min.^{44,45} Priming volume of the P-PAL circuit is reported which includes fiber bundle area, pump area, and conduits.⁴⁶ Pressure drop of gas exchange region not reported, this device incorporates a pump to generate pressure and is intended for venoarterial use. CO₂ removal data not reported. ***CO₂ exchange efficiency was taken as the average of the highest values achieved during in-vivo testing (n=3).

Comparison between MLung and commercial oxygenators						
Device	Surface Area (m ²)	Rated Flow (L/min)	Pressure Drop at Rated Flow (mmHg)	Priming Volume (mL)	Gas Exchange Efficiency at Rated Flow (mL/min/m ²)	
					O ₂	CO ₂
Terumo Capiiox RX05	0.5	1.5	110	43	150	500 [†]
Maquet Quadrox Neonatal	0.38	1.5	58	40	197	189
Maquet Quadrox Pediatric	0.8	2.8	60 (1.5 L/min)	99	175	250
Soren Dideco D100	0.22	0.7	175	47	159	145
Novalung iLA	1.3	N/A [‡]	Data not available	175	85 [‡]	212 [‡]
Pedipump Lung	0.3	2.5	150	110	400	343*
P-PAL	0.3	N/A**	N/A**	270**	310**	N/A
MLung (Single inlet)	0.28	2.0	106	47	357	714
Pediatric MLung	0.13	1.0	25	68±7	349	343±90***